This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Analysis of effectiveness
The outcome measure used in the analysis was the accuracy of the SMIS in comparison with the reference methods. The SMIS result was considered correct if the correct species name of an isolate was listed on the software report as the first choice, regardless of the magnitude of the similarity index value accompanying that species' name. If the SMIS and the reference method identifications differed, or the SMIS was unable to identify an isolate, a fresh extract of a new subculture of the isolate on the Midlebrool 7H10 agar was analysed in the SMIS a second time. If an isolate was misidentified by the SMIS when first tested, it was counted as a misidentification, regardless of whether it was correctly or incorrectly identified when it was reanalysed. If it was unidentified by the SMIS when first tested, and then correctly or incorrectly identified when the chromatography was repeated, it was counted as either a correct or incorrect identification. The predictive values for the accuracy of SMIS software assignments of unknown mycobacterial isolates to each of the mycobacterial species or group was determined. More specifically, the number of correct SMIS calls for a given species was divided by the total number of times that isolates were correctly or incorrectly assigned by the SMIS to that species.
Effectiveness results
Of the 370 isolates, 327 (88%) were named by the SMIS software and 43 (12%) were unidentified.
The SMIS correctly named 279 isolates (75% of the total number of mycobacterial isolates and 85% of the isolates given a name by the system).
The number of isolates misidentified was 48 (13% of the total isolates studied and 15% of the isolates named by the system).
The correct identification ranged from 4 to 100% depending on the species of the isolates.
Only 4 isolates (M. lentiflavum, M. phlei, M. smegmatis and M. vaccae) for which the SMIS software library had no data were tested. All 4 isolates were correctly called "no match" (unidentified) by the system. The predictive value of the SMIS for species identification was 85% overall, but it ranged from 27 to 100%.
Of the 370 isolates studied, 115 (31%) had to be analysed a second time because the initial results were either incorrect (38 isolates), or the isolates were unidentified (77 isolates). For these 115 retested isolates, the SMIS identification for 33 (29%) changed from incorrect or unidentified to correct. Results from another 28 (24%) remained incorrect, results for 43 (37%) remained unidentified, results for only 1 (1%) changed from incorrect to unidentified, and results of 10 (9%) changed from unidentified to incorrect.
In many cases, a mycobacterial isolate that had been misidentified could be easily identified correctly by calculating the relative peak height ratios (RPHRs) of mycolic acids and comparing these figures with known values for species with similar chromatographic profiles of mycolic acids. By using RPHRs and relative retention times, all 48 SMISmisidentified isolates and 39 (91%) of the 43 SMIS-unidentified isolates could be correctly identified without additional tests.
Clinical conclusions
The effectiveness study showed that the SMIS, combined with a knowledge of RPHRs, relative retention times and phenotic characteristics, represented a rapid and accurate diagnostic strategy.
Methods used to derive estimates of effectiveness
Some assumptions on the efficacy of the comparators were made.
Estimates of effectiveness and key assumptions
The authors assumed that all the reference tests had 100% accuracy in detecting mycobacteria.
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Measure of benefits used in the economic analysis
The health outcomes were left disaggregated and no summary benefit measure was used in the economic study. In effect, a cost-consequences analysis was carried out.
Direct costs
Discounting was not relevant since the costs were incurred during a short time. The unit costs were not reported separately from the quantities of resources used. The health services included in the economic evaluation were materials and labour. Further details of the cost analysis were not provided. The cost/resource boundary of the study, the source of the data and the price year were not reported.
Statistical analysis of costs
The costs were treated deterministically.
Indirect Costs
The indirect costs were not considered.
Currency

US dollars ($).
Sensitivity analysis
Sensitivity analyses were not conducted.
Estimated benefits used in the economic analysis
See the 'Effectiveness Results' section.
Cost results
The total costs associated with the test of each isolate and control were: The initial software and hardware costs of the SMIS were just over $50,000 and an annual service contract was about $4,000.
Synthesis of costs and benefits
The costs and benefits were not combined because a cost-consequences analysis was performed.
